News

Hyphens Pharma to develop and commercialise ByfavoR procedural sedation drug in Singapore

SGX-Catalist listed Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group, has just announced that its subsidiary, Hyphens Pharma Pte. Ltd., has signed an exclusive sub-license and supply agreement with Hana Pharm Co., Ltd. to develop...

AustinPx Expands Development, Manufacturing Technologies

AustinPx, a contract development and manufacturing organization (CDMO) specializing in analytical and formulation development services and cGMP manufacturing for small molecule drugs, expanded its capabilities. The company has added new spray drying and encapsulation capabilities and expanded its GMP...

FDA Discussion Paper On AI And ML Aiming Drug Development

A discussion paper has been published by the US FDA that aims at complementing and informing future guidance on artificial intelligence (AI) and machine learning (ML) usage in drug development. The purpose of this paper is to initiate an...

Tablet Coatings Market Poised for Remarkable Growth by 2031

The worldwide tablet coatings sector generated $2.2 billion in 2021 and is projected to reach $4.1 billion by 2031, growing at a CAGR of 6.6% from 2022 to 2031. Key takeaways include: Increasing pharmaceutical demand: Growing global demand for pharmaceuticals...

EMA Lifts Business Continuity Measures Due To Pandemic Shift

The European Medicines Agency (EMA) and the European Medicines regulatory network have announced the lifting of COVID-19 business continuity measures, signifying a step towards normalizing regulatory processes as pandemic trends shift. These measures were introduced in 2020 to prioritize...

Pharma.Aero and Neutral Air Partner sign MoU to support life science and MedTech transportation

Pharma.Aero and Neutral Air Partner have come together to work collaboratively towards improving the reliability, security and speed of life science and MedTech-related airfreight shipping. Under their memorandum of understanding (MoU), the two partners will conduct joint research and studies,...

Bayer, Bicycle Therapeutics Partner on Targeted Radionuclide Therapies in Oncology

Bayer and Bicycle Therapeutics Limited, a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle), have entered a strategic collaboration to discover, develop, manufacture, and commercialize Bicycle radio conjugates for multiple...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read